Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)

after randomization of patients in both groups (Plavix or Pidogrel), the measure of platelet activity by the VerifyNow assay, 4 to 12 hours after the loading dose of 600mg or after the last dose of clopidogrel for patients on maintenance dose. The VerifyNow assay will determine: - The PRU:-P2Y12 Reaction Units-

-% Of platelet inhibition It will be considered low responder or clopidogrel resistant patient with PRU> 235 or %inhibition <15%.

Monitoring of patients included in the study will take place over a period of 12 months, MACE will be notified and dated. MACE criteria are: angina, myocardial infarction, coronary angioplasty, coronary artery bypass graft, and stroke.

Each hemorrhagic event will be notified and classified according to the GUSTO scale.

Inclusion criteria

• Male or female,
• Old (e) over 20 years
• Patients hospitalized for acute coronary syndrome (Whatever the T and troponin)
• Patients with proven coronary candidates for treatment with clopidogrel (who received a loading dose of 600mg over 2 hours and treated with 75mg / d of clopidogrel for longer than 7 days)

Exclusion criteria

• Patients unwilling.
• Patient participating in another study.
• Patients with cardiogenic shock
• Patient on anti GpIIbIIIa or stopped less than 72 hours before the test aggregability
• Patients scheduled for surgery in less than 6 months.
• Patients candidates for coronary angioplasty
• Patients who underwent TAC + / - bare stent fewer than 30 days.
• Patients who underwent stenting with ATC active there is less than 12 months.
• ischemic stroke older than 6 weeks.
• History of hemorrhagic stroke (any time)
• Patients on warfarin or candidates
• Patients with a different anti ADP (ticlopidine, prasugrel)
• Patients with indication for clopidogrel-cons (side effects, bleeding ...)
• Thrombocytopenia <100000/mm3
• anemia (Ht <30%)
• Thrombocythaemia (Ht> 52%)
• Patients seeking treatment for an elective forms of Clopidogrel.
• Pregnancy